Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 4Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, B-Cell, Marginal Zone 1

Interventions

Specimen Handling 218Magnetic Resonance Spectroscopy 194pembrolizumab 185Carboplatin 160Biopsy 129Cisplatin 128Nivolumab 119Paclitaxel 107Cyclophosphamide 104Radiotherapy 99Gemcitabine 96Dexamethasone 86durvalumab 83atezolizumab 70Rituximab 66Radiation 64Lenalidomide 64Doxorubicin 63Pemetrexed 61Bevacizumab 58Etoposide 56Docetaxel 56olaparib 50Ipilimumab 49Fluorouracil 48Taxes 47Prednisone 47Oxaliplatin 46Vincristine 45Cytarabine 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × orelabrutinib × 90 days × Clear all
NCT07480863 2026-04-02

Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2 Active not recruiting
65 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

Data powered by HemOnc (CC BY 4.0) Colophon âš¡